Unknown

Dataset Information

0

Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics.


ABSTRACT: In childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), cytogenetic abnormalities remain important diagnostic and prognostic tools. A number of well-established abnormalities are routinely used in risk stratification for treatment. These include high hyperdiploidy and ETV6-RUNX1 fusion, classified as good risk, while Philadelphia chromosome (Ph) positive ALL and rearrangements of the KMT2A (MLL) gene define poor risk. A poor risk subgroup of intrachromosomal amplification of chromosome 21 (iAMP21-ALL) has been described, in which intensification of therapy has greatly improved outcome. Until recently, no consistent molecular features were defined in around 30% of BCP-ALL (known as B-other-ALL). Recent studies are classifying them into distinct subgroups, some with clear potential for novel therapeutic approaches. For example, in 1 poor risk subtype, known as Ph-like/BCR-ABL1-like ALL, approximately 10% have rearrangements of ABL-class tyrosine kinases: including ABL1, ABL2, PDGFRB, PDGFRA, and CSF1R. Notably, they show a poor response to standard chemotherapy, while they respond to treatment with tyrosine kinase inhibitors, such as imatinib. In other Ph-like-ALL patients, deregulation of the cytokine receptor, CRLF2, and JAK2 rearrangements lead to activation of the JAK-STAT signaling pathway, implicating a specific role for JAK inhibitors in their treatment. Other novel subgroups within B-other-ALL are defined by the IGH-DUX4 translocation, related to deletions of the ERG gene and a good outcome, while fusions involving ZNF384, MEF2D, and intragenic PAX5 amplification (PAX5 AMP) are linked to a poor outcome. Continued genetic screening will eventually lead to complete genomic classification of BCP-ALL and define more molecular targets for less toxic therapies.

SUBMITTER: Schwab C 

PROVIDER: S-EPMC6746003 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics.

Schwab Claire C   Harrison Christine J CJ  

HemaSphere 20180620 4


In childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), cytogenetic abnormalities remain important diagnostic and prognostic tools. A number of well-established abnormalities are routinely used in risk stratification for treatment. These include high hyperdiploidy and <i>ETV6-RUNX1</i> fusion, classified as good risk, while Philadelphia chromosome (Ph) positive ALL and rearrangements of the <i>KMT2A</i> (<i>MLL</i>) gene define poor risk. A poor risk subgroup of intrachromosomal am  ...[more]

Similar Datasets

| S-EPMC3621335 | biostudies-literature
| S-EPMC8490503 | biostudies-literature
| S-EPMC2806782 | biostudies-literature
| S-EPMC6833142 | biostudies-literature
| S-EPMC5865415 | biostudies-literature
| S-EPMC4362237 | biostudies-literature
| S-EPMC3575759 | biostudies-literature
| S-EPMC9694201 | biostudies-literature
| S-EPMC10756719 | biostudies-literature
| S-EPMC7370557 | biostudies-literature